Key Takeaways
- • OneBio Venture Studio has achieved a R100 million (South African Rand) first close for its Fund II, marking a significant fundraising milestone for the biotech-focused venture studio operating in Africa.
- • The fund targets early-stage life sciences and biotechnology investments, positioning OneBio to deploy capital across the African biotech ecosystem.
- • This fundraising demonstrates institutional investor appetite for dedicated venture capital vehicles focused on Africa's emerging biotech sector.
Summary
OneBio Venture Studio has reached its first close at R100 million for Fund II, signaling continued institutional interest in venture capital deployment across Africa's life sciences sector. The rand-denominated fund close represents a significant commitment to building out the venture studio's investment capacity in biotech and related life sciences opportunities across the continent.
The achievement of a first close indicates that OneBio has successfully secured commitments from limited partners to begin deploying capital from Fund II. This milestone typically signals momentum in fundraising efforts and provides the venture studio with dry powder to make initial investments while continuing to pursue additional commitments toward a target fund size.
OneBio's focus on venture studio operations—which blend investment management with hands-on company building and acceleration services—positions it within a specialized segment of African venture capital that combines traditional venture funding with operational support for early-stage biotech founders. The R100 million first close suggests investor confidence in both the venture studio's track record and the growth potential of Africa's biotechnology ecosystem.
The achievement of a first close indicates that OneBio has successfully secured commitments from limited partners to begin deploying capital from Fund II. This milestone typically signals momentum in fundraising efforts and provides the venture studio with dry powder to make initial investments while continuing to pursue additional commitments toward a target fund size.
OneBio's focus on venture studio operations—which blend investment management with hands-on company building and acceleration services—positions it within a specialized segment of African venture capital that combines traditional venture funding with operational support for early-stage biotech founders. The R100 million first close suggests investor confidence in both the venture studio's track record and the growth potential of Africa's biotechnology ecosystem.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.